Current Report Filing (8-k)
May 14 2018 - 6:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE
ACT OF 1934
Date of Report (Date of Earliest Event Reported):
May 11,
2018
BIOSPECIFICS TECHNOLOGIES CORP.
(Exact name of registrant as specified in its charter)
Delaware
|
001-34236
|
11-3054851
|
(State or Other Jurisdiction
|
(Commission File Number)
|
(I.R.S. Employer
|
Of Incorporation)
|
|
Identification No.)
|
35 Wilbur Street
Lynbrook, NY 11563
(Address of Principal Executive Office) (Zip Code)
516.593.7000
(Registrants telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2 of the Securities Exchange Act of 1934.
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. [ ]
INTRODUCTORY COMMENT
Throughout
this Current Report on Form 8-K, the terms we, us, our and Company refer
to BioSpecifics Technologies Corp.
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On
May 11, 2018, the Company entered into an amendment (the Amendment) to the
Rights Agreement, dated as of May 14, 2002 and previously amended June 19, 2003,
February 3, 2011, March 5, 2014, and again on May 27, 2016 between the Company
and Worldwide Stock Transfer, LLC (successor in interest to OTC Corporate
Transfer Service Company), as rights agent (the Rights Agreement). The Rights
Agreement pertains to those certain contingent rights to purchase Series B
Junior Participating Preferred Stock, par value $0.50, of the Company.
The
Amendment extends the Final Expiration Date of the Rights Agreement (as
defined in the Rights Agreement) for an additional two years, to May 31, 2020.
The
foregoing description of the Amendment does not purport to be complete and is
qualified in its entirety by reference to the Amendment that will be filed
subsequently as an exhibit to our Quarterly Report on Form 10-Q for the quarter
ended June 30, 2018.
ITEM 3.03 MATERIAL MODIFICATION TO RIGHTS OF SECURITY
HOLDERS
The information set forth under Item 1.01 Entry
into a Material Definitive Agreement of this Current Report on Form 8-K is
incorporated into this Item 3.03 by reference.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Date: May 11, 2018
|
BIOSPECIFICS TECHNOLOGIES CORP.
|
|
|
|
|
|
/s/ Thomas L. Wegman
|
|
Thomas L. Wegman
|
|
President
|
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From Sep 2023 to Sep 2024